Astria Therapeutics (NASDAQ:ATXS) Trading Down 5.9%

Astria Therapeutics, Inc. (NASDAQ:ATXS) dropped 5.9% during mid-day trading on Wednesday . The company traded as low as $10.66 and last traded at $10.66. Approximately 42,826 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 691,102 shares. The stock had previously closed at $11.33.

Analysts Set New Price Targets

Several brokerages recently weighed in on ATXS. Wedbush reiterated an “outperform” rating and issued a $22.00 price target on shares of Astria Therapeutics in a report on Tuesday, August 13th. Oppenheimer raised their price objective on Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a report on Tuesday, August 13th. Evercore ISI raised Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Finally, TD Cowen started coverage on shares of Astria Therapeutics in a report on Monday, July 29th. They issued a “buy” rating and a $35.00 price target for the company. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $25.20.

Astria Therapeutics Price Performance

The company’s 50 day moving average price is $11.09 and its two-hundred day moving average price is $11.08. The stock has a market capitalization of $598.05 million, a PE ratio of -4.60 and a beta of 0.71.

Astria Therapeutics (NASDAQ:ATXS) last issued its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). Analysts forecast that Astria Therapeutics, Inc. will post -1.66 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. RA Capital Management L.P. acquired a new position in shares of Astria Therapeutics in the 1st quarter worth approximately $62,115,000. Perceptive Advisors LLC boosted its position in shares of Astria Therapeutics by 82.9% during the fourth quarter. Perceptive Advisors LLC now owns 4,004,070 shares of the biotechnology company’s stock worth $30,751,000 after buying an additional 1,814,608 shares during the period. Vanguard Group Inc. grew its stake in shares of Astria Therapeutics by 23.4% in the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock valued at $35,693,000 after buying an additional 480,184 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Astria Therapeutics by 13.5% in the 2nd quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock valued at $16,763,000 after buying an additional 218,518 shares during the period. Finally, Armistice Capital LLC acquired a new position in Astria Therapeutics during the 4th quarter worth about $12,119,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.